How do you choose between Atezolizumab/Bevacizumab (IMbrave 150) versus Durvalumab/Tremelimumab (HIMALAYA) in first-line metastatic hepatocellular cancer?

I use a range of factors, discussed here and here, when deciding between atezo/bev and STRIDE regimens in my patients with advanced HCC.

Summarily, both regimens demonstrated clinical benefit in patients with advanced HCC with side-effect profiles expected for the individual agents. The choice of reg...